SCHEMBL29626502

SCHEMBL29626502

CN1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 12/20 0.82
PTAFR P25105 3/20 0.77
FNTA P49354 4/20 0.76
FNTB P49356 4/20 0.76
SLC6A15 Q9H2J7 4/20 0.76
CHRM2 P08172 2/20 0.72
HTR1A P08908 2/20 0.72
CHRM1 P11229 2/20 0.72
DRD2 P14416 2/20 0.72
HTR2A P28223 2/20 0.72
HTR2C P28335 2/20 0.72
ADRA1A P35348 2/20 0.72
OPRK1 P41145 2/20 0.72
HTR2B P41595 2/20 0.72
KCNH2 Q12809 2/20 0.72
MEN1 O00255 1/20 0.72
LMNA P02545 1/20 0.72
ADRB2 P07550 1/20 0.72
CHRM4 P08173 1/20 0.72
ABCB1 P08183 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31384618 1.00 HRH1 (0.82) HRH1PTAFRFNTAFNTBSLC6A15
SCHEMBL4460572 1.00 HRH1 (0.82) HRH1PTAFRFNTAFNTBSLC6A15
SCHEMBL20777155 0.89 PTAFR (0.75) HRH1PTAFRFNTAFNTBSLC6A15
SCHEMBL8958672 0.89 PTAFR (0.75) HRH1PTAFRFNTAFNTBSLC6A15
SCHEMBL10123931 0.88 HRH1 (1.00) HRH1PTAFRFNTAFNTBSLC6A15
SCHEMBL10108533 0.88 HRH1 (0.72) HRH1PTAFRFNTAFNTBSLC6A15
SCHEMBL11925299 0.88 HRH1 (1.00) HRH1PTAFRFNTAFNTBSLC6A15
SCHEMBL26488239 0.88 SLC6A15 (0.79) HRH1PTAFRFNTAFNTBSLC6A15
SCHEMBL8876967 0.87 PTAFR (1.00) HRH1PTAFRFNTAFNTBSLC6A15
SCHEMBL31305643 0.87 PTAFR (1.00) HRH1PTAFRFNTAFNTBSLC6A15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114616229-B Tricyclic compounds and pharmaceutical uses thereof 镇斗生物科技股份公司 2024-09-03 CN claimed
CN-114616229-A Tricyclic compounds and pharmaceutical uses thereof 镇斗生物科技股份公司 2022-06-10 CN claimed
CN-119395165-A Method for measuring impurities in desloratadine oral solution 深圳市贝美药业有限公司 2025-02-07 CN disclosed
CN-114616229-B Tricyclic compounds and pharmaceutical uses thereof 镇斗生物科技股份公司 2024-09-03 CN disclosed
US-20230002349-A1 TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF JD BIOSCIENCE INC. (KR) 2023-01-05 US disclosed
EP-4053116-A1 TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF JD Bioscience Inc. (KR) 2022-09-07 EP disclosed
CN-114616229-A Tricyclic compounds and pharmaceutical uses thereof 镇斗生物科技股份公司 2022-06-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002349-A1 TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TPH1, SLC6A4, TPH2 HRH1 1035/4885PTAFR 1723/4885FNTA 3206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.